Kidney Int. 2026 Sep;110(3):522-525. doi: 10.1016/j.kint.2026.06.020.
ABSTRACT
Wang et al. showcase a green mamba-derived compound, MQ232, which interferes with cyst growth in a mouse model of autosomal dominant polycystic kidney disease, similar to the only approved drug for autosomal dominant polycystic kidney disease treatment, tolvaptan. However, the authors reveal cyclic adenosine monophosphate-dependent and -independent components in MQ232's mode of action and gender differences in efficacy. Therefore, MQ232 may pave the way to novel treatment options for autosomal dominant polycystic kidney disease.
PMID:42624539 | DOI:10.1016/j.kint.2026.06.020